AAVANTIBIO, INC.

Profile

Company Names

AAVANTIBIO, INC.

Addresses

747 SW 2ND AVE, IMB 31, GAINESVILLE, FL 32601

Phone Numbers

352-448-6551

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2019

State Incorporated:

DELAWARE

Total Amount Raised:

$41,752,059.00

Number of Funding Rounds:

1
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
1
2020-10-21 
$41,752,059.00 
$106,856,458.00 
$65,104,399.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
BARRY 
J. 
BYRNE, M.D., PH.D. 
EXECUTIVE OFFICER, DIRECTOR
AAVANTIBIO, INC.
MANUELA 
 
CORTI, PT, PH.D. 
EXECUTIVE OFFICER, DIRECTOR
AAVANTIBIO, INC.
BO 
 
CUMBO 
EXECUTIVE OFFICER, DIRECTOR
AAVANTIBIO, INC.
ELLEN 
 
HUKKELHOVEN, PH.D. 
EXECUTIVE OFFICER, DIRECTOR
AAVANTIBIO, INC.
PHILIP 
R. 
JOHNSON, M.D. 
EXECUTIVE OFFICER, DIRECTOR
AAVANTIBIO, INC.   |  INTERIUS BIOTHERAPEUTICS, INC.
BENJAMIN 
 
LUND 
EXECUTIVE OFFICER, DIRECTOR
AAVANTIBIO, INC.   |  INTERIUS BIOTHERAPEUTICS, INC.
JAKE 
 
SIMSON 
EXECUTIVE OFFICER, DIRECTOR
AAVANTIBIO, INC.   |  DICE MOLECULES HOLDINGS, LLC   |  CEDILLA THERAPEUTICS, INC.   |  CONVERGENT THERAPEUTICS, INC.   |  SEPTERNA, INC.   |  OUTPACE BIO, INC.   |  VIVACE THERAPEUTICS, INC.
DOUGLAS 
J. 
SWIRSKY 
EXECUTIVE OFFICER, DIRECTOR
GENVEC INC   |  FIBROCELL SCIENCE, INC.   |  CELLECTAR BIOSCIENCES, INC.   |  AAVANTIBIO, INC.   |  NEUROBO PHARMACEUTICALS, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2020-11-19
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2020-10-21 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#